NUCLIDIUM

NUCLIDIUM is setting new standards in the field of precision oncology by developing first-class copper-based radiopharmaceuticals, enabling targeted cancer treatment and diagnosis with the highest accuracy and accessibility. Our flexible CuTraceTM platform combines copper radionuclides with a variety of highly specific cancer-targeting molecules to rapidly develop new diagnostic and therapeutic procedures. The resulting portfolio leverages the unique properties of copper to enhance safety and efficacy, delivering favorable economic benefits for hospitals and patients. NUCLIDIUM’s differentiated "diagnostics-to-therapy" approach reduces risks along our development pathway. With innovation at our core, we overcome supply constraints in manufacturing and distribution, bringing greater flexibility to medical facilities. We are a diverse, interdisciplinary team committed to transforming precision radio-oncology to deliver real benefits to cancer patients.